The European Medicines Agency (EMA) has started the assessment procedure for a new drug against the coronavirus: Evusheld. Swedish-British manufacturer AstraZeneca developed the drug to prevent Covid-19 in adults.
The first test results showed that the medicine – which consists of the active ingredients Tixagevimab and Cilgavimab – can be used effectively to protect against the disease. Experts are now looking at all the scientific data and tests and will weigh up the pros and cons of the drug. It is not known when they will make their final verdict.
According to the EMA, AstraZeneca has not yet applied for approval for the European market. Until now, only the medicine Remdesivir has been approved as a special corona medicine in the EU. Approval procedures are still ongoing for five other preparations.